ONTY's (Biomira's) main opportunities, Theratope and BLP-25, collapsed following unsupportable showings in phase 3 trials. The small molecules were added in the hope of creating a pipeline particularly to cover the eventuality of BLP-25 (Stimuvax) failure. These largely fell by the wayside too. ONT- 10 should have been well under way in Phase 2 trials by now, but support from Merck KgAa no longer seems to be an option given the results from the Stimuvax trials.
The company seems to be a bit of a shell of its former self, largely a result of the Phase 3 failures of the Biomira products. How much of the failure is due to management failure, is something you will have to decide for yourself.
You are trying to foist a wrong message on the readers here. It shows very little understanding of ONTY's situation. You should be very worried that your source for investment advice would be so misleading.
The analysts were wrong; this is the only company worth looking at? Why MFST’s latest product launch could take it past $12 and why now is the best time to buy the
Significantly greater daily average voume for the past week. No PPS depression after secondary at 1.50. Both ONT-wo and ONT-380 are early phase but each has a compelling story.
With the death of Stimuvax, could we have a new partnership r/t ONT-10? if you really want to speculate, how about. . . . . . . . . . . . ?